Share on StockTwits

Vertex Pharmaceuticals (NASDAQ:VRTX) Director Elaine Ullian sold 5,000 shares of the stock on the open market in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $95.21, for a total transaction of $476,050.00. Following the completion of the sale, the director now directly owns 5,265 shares of the company’s stock, valued at approximately $501,281. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on VRTX shares. Analysts at Goldman Sachs raised their price target on shares of Vertex Pharmaceuticals to $109.00 in a research note on Wednesday, June 25th. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, June 25th. They now have a $136.00 price target on the stock, up previously from $103.00. Finally, analysts at Sanford C. Bernstein raised their price target on shares of Vertex Pharmaceuticals from $65.00 to $107.00 in a research note on Wednesday, June 25th. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $100.41.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 0.79% during mid-day trading on Thursday, hitting $98.80. 1,300,894 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a 1-year low of $58.06 and a 1-year high of $98.80. The stock has a 50-day moving average of $74.57 and a 200-day moving average of $74.64. The company’s market cap is $23.336 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.03. The company had revenue of $118.50 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter in the previous year, the company posted $0.03 earnings per share. The company’s revenue for the quarter was down 63.9% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $-2.88 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.